두개내 동맥류 시장 규모, 점유율, 동향 분석 보고서 : 제품 유형별, 용도별, 동맥류 종류별, 지역별, 부문별 예측(2026-2033년)

Intracranial Aneurysm Market Summary

The global intracranial aneurysm market size was estimated at USD 1.71 billion in 2025 and is projected to reach USD 3.50 billion by 2033, growing at a CAGR of 8.58% from 2026 to 2033. The growth is primarily driven by the increasing prevalence of cerebrovascular disorders, including hypertension and atherosclerosis, which are major risk factors for aneurysm formation.

Advances in medical technology, particularly in endovascular interventions such as coil embolization and flow diverters, have improved treatment outcomes and reduced procedural risks, encouraging wider adoption. In addition, the development of minimally invasive surgical devices and image-guided neurosurgical systems has facilitated earlier detection and treatment, further boosting market demand.

The growing prevalence of brain aneurysms is a key driver of the intracranial aneurysm market. As the number of patients affected by cerebrovascular disorders, hypertension, smoking, and other lifestyle-related risk factors rises, the demand for early diagnosis and effective treatment solutions increases. This is further supported by the aging global population, which is more susceptible to aneurysm formation and rupture. Early detection through advanced imaging techniques, coupled with minimally invasive treatment options like endovascular coiling and flow diversion, has expanded the patient pool seeking intervention, thereby fueling market growth. Additionally, increasing awareness among clinicians and patients about the risks associated with untreated brain aneurysms contributes to higher adoption of therapeutic procedures, making brain aneurysms a central factor driving the market. According to the Hereditary Brain Aneurysm Support 2025, unruptured brain aneurysms, localized bulges or swellings in the brain's blood vessels, are relatively common, affecting about 3% of the UK population, or roughly 2 million people. While most aneurysms remain asymptomatic and do not cause problems, a small number, between 3,000 and 5,000 cases each year, rupture, with approximately half of these resulting in fatal outcomes.

Global Intracranial Aneurysm Market Report Segmentation

This report forecasts revenue growth at country and states level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global intracranial aneurysm market report based on product type, aneurysm type, end use, and region:

• Product Type Outlook (Revenue, USD Million, 2021 - 2033)
• Surgical Clipping
• Endovascular Coiling
• Flow Diverters
• Others
• Aneurysm Type Outlook (Revenue, USD Million, 2021 - 2033)
• Ruptured Intracranial Aneurysms
• Unruptured Intracranial Aneurysms
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Clinics
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Third Party Perspective
  • 1.3.6. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights Outlook

Chapter 3. Intracranial Aneurysm Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Ancillary market outlook
• 3.2. User Perspective Analysis
  • 3.2.1. Consumer behavior analysis
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
    • 3.3.1.1. Rising detection of unruptured aneurysms
    • 3.3.1.2. Measurable disease burden from hemorrhagic stroke/subarachnoid hemorrhage (SAH)
    • 3.3.1.3. Wider clinical adoption of endovascular technologies
  • 3.3.2. Market Restraint Analysis
    • 3.3.2.1. Uncertainty about natural history and rupture risk for many small, incidentally found UIAs
    • 3.3.2.2. Procedural safety constraints and periprocedural therapy requirements
  • 3.3.3. Market Opportunity Analysis
    • 3.3.3.1. Improved imaging & AI-assisted screening to systematically find missed aneurysms
    • 3.3.3.2. Expanding clinical indications for flow diversion and adjunct techniques
    • 3.3.3.3. Aging populations and increased neuroimaging for other diseases
  • 3.3.4. Market Challenges Analysis
    • 3.3.4.1. Access, disparities and real-world outcomes variance
    • 3.3.4.2. Clinical decision complexity and guideline heterogeneity
• 3.4. Intracranial Aneurysm Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape

Chapter 4. Intracranial Aneurysm Market: Product Type Estimates & Trend Analysis

• 4.1. Definitions and Scope
• 4.2. Product Type Market Share, 2021 & 2033
• 4.3. Segment Dashboard
• 4.4. Global Intracranial Aneurysm Market by Product Type Outlook
• 4.5. Market Size & Forecasts and Trend Analyses, 2025 to 2033 for the following:
• 4.6. Surgical Clipping
  • 4.6.1. Surgical clipping market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6.2. Surgical clipping market procedure volume estimates and forecasts, 2021 - 2033
• 4.7. Endovascular Coiling
  • 4.7.1. Endovascular coiling market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.7.2. Endovascular coiling market procedure volume estimates and forecasts, 2021 - 2033
• 4.8. Flow Diverters
  • 4.8.1. Flow diverters market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.8.2. Flow diverters market procedure volume estimates and forecasts, 2021 - 2033
• 4.9. Others
  • 4.9.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Intracranial Aneurysm Market: Aneurysm Type Estimates & Trend Analysis

• 5.1. Definitions and Scope
• 5.2. Aneurysm Type Market Share, 2021 & 2033
• 5.3. Segment Dashboard
• 5.4. Global Intracranial Aneurysm Market by Aneurysm Type Outlook
• 5.5. Procedural Volume
• 5.6. Market Size & Forecasts and Trend Analyses, 2025 to 2033 for the following:
• 5.7. Ruptured intracranial aneurysms
  • 5.7.1. Ruptured intracranial aneurysms market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.8. Unruptured intracranial aneurysms
  • 5.8.1. Unruptured intracranial aneurysms market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Intracranial Aneurysm Market: End Use Estimates & Trend Analysis

• 6.1. Definitions and Scope
• 6.2. End Use Market Share, 2021 & 2033
• 6.3. Segment Dashboard
• 6.4. Global Intracranial Aneurysm Market by End Use Outlook
• 6.5. Market Size & Forecasts and Trend Analyses, 2025 to 2033 for the following:
• 6.6. Hospitals
  • 6.6.1. Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.7. Clinics
  • 6.7.1. Clinics market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Intracranial Aneurysm Market: Regional Estimates & Trend Analysis By Aneurysm Type, By End Use

• 7.1. Regional market share analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Regional Market Share and Leading Players, 2025
  • 7.4.1. North America
  • 7.4.2. Europe
  • 7.4.3. Asia Pacific
  • 7.4.4. Latin America
  • 7.4.5. Middle East and Africa
• 7.5. Market Size & Forecasts, and Trend Analysis, 2021 TO 2033:
• 7.6. North America
  • 7.6.1. Market estimates and forecast, 2021 - 2033 (Revenue, USD Million)
  • 7.6.2. U.S.
    • 7.6.2.1. Key country dynamics
      • 7.6.2.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.6.2.1.1.1. Incidence Analysis
        • 7.6.2.1.1.2. Prevalence Analysis
        • 7.6.2.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. U.S. market estimates and forecasts, 2021 - 2033
  • 7.6.3. Canada
    • 7.6.3.1. Key country dynamics
      • 7.6.3.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.6.3.1.1.1. Incidence Analysis
        • 7.6.3.1.1.2. Prevalence Analysis
        • 7.6.3.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Canada market estimates and forecasts, 2021 - 2033
  • 7.6.4. Mexico
    • 7.6.4.1. Key country dynamics
      • 7.6.4.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.6.4.1.1.1. Incidence Analysis
        • 7.6.4.1.1.2. Prevalence Analysis
        • 7.6.4.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. Reimbursement scenario
    • 7.6.4.5. Mexico market estimates and forecasts, 2021 - 2033
• 7.7. Europe
  • 7.7.1. Germany
    • 7.7.1.1. Key country dynamics
      • 7.7.1.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.7.1.1.1.1. Incidence Analysis
        • 7.7.1.1.1.2. Prevalence Analysis
        • 7.7.1.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.7.1.2. Competitive scenario
    • 7.7.1.3. Regulatory framework
    • 7.7.1.4. Reimbursement scenario
    • 7.7.1.5. Germany market estimates and forecasts, 2021 - 2033
  • 7.7.2. UK
    • 7.7.2.1. Key country dynamics
      • 7.7.2.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.7.2.1.1.1. Incidence Analysis
        • 7.7.2.1.1.2. Prevalence Analysis
        • 7.7.2.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. UK market estimates and forecasts, 2021 - 2033
  • 7.7.3. France
    • 7.7.3.1. Key country dynamics
      • 7.7.3.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.7.3.1.1.1. Incidence Analysis
        • 7.7.3.1.1.2. Prevalence Analysis
        • 7.7.3.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. France market estimates and forecasts, 2021 - 2033
  • 7.7.4. Italy
    • 7.7.4.1. Key country dynamics
      • 7.7.4.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.7.4.1.1.1. Incidence Analysis
        • 7.7.4.1.1.2. Prevalence Analysis
        • 7.7.4.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. Italy market estimates and forecasts, 2021 - 2033
  • 7.7.5. Spain
    • 7.7.5.1. Key country dynamics
      • 7.7.5.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.7.5.1.1.1. Incidence Analysis
        • 7.7.5.1.1.2. Prevalence Analysis
        • 7.7.5.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. Spain market estimates and forecasts, 2021 - 2033
  • 7.7.6. Denmark
    • 7.7.6.1. Key country dynamics
      • 7.7.6.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.7.6.1.1.1. Incidence Analysis
        • 7.7.6.1.1.2. Prevalence Analysis
        • 7.7.6.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.7.6.2. Competitive scenario
    • 7.7.6.3. Regulatory framework
    • 7.7.6.4. Reimbursement scenario
    • 7.7.6.5. Denmark market estimates and forecasts, 2021 - 2033
  • 7.7.7. Sweden
    • 7.7.7.1. Key country dynamics
      • 7.7.7.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.7.7.1.1.1. Incidence Analysis
        • 7.7.7.1.1.2. Prevalence Analysis
        • 7.7.7.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.7.7.2. Competitive scenario
    • 7.7.7.3. Regulatory framework
    • 7.7.7.4. Reimbursement scenario
    • 7.7.7.5. Sweden market estimates and forecasts, 2021 - 2033
  • 7.7.8. Norway
    • 7.7.8.1. Key country dynamics
      • 7.7.8.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.7.8.1.1.1. Incidence Analysis
        • 7.7.8.1.1.2. Prevalence Analysis
        • 7.7.8.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.7.8.2. Competitive scenario
    • 7.7.8.3. Regulatory framework
    • 7.7.8.4. Reimbursement scenario
    • 7.7.8.5. Norway market estimates and forecasts, 2021 - 2033
• 7.8. Asia Pacific
  • 7.8.1. China
    • 7.8.1.1. Key country dynamics
      • 7.8.1.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.8.1.1.1.1. Incidence Analysis
        • 7.8.1.1.1.2. Prevalence Analysis
        • 7.8.1.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.8.1.2. Competitive scenario
    • 7.8.1.3. Regulatory framework
    • 7.8.1.4. Reimbursement scenario
    • 7.8.1.5. China market estimates and forecasts, 2021 - 2033
  • 7.8.2. Japan
    • 7.8.2.1. Key country dynamics
      • 7.8.2.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.8.2.1.1.1. Incidence Analysis
        • 7.8.2.1.1.2. Prevalence Analysis
        • 7.8.2.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. Reimbursement scenario
    • 7.8.2.5. Japan market estimates and forecasts, 2021 - 2033
  • 7.8.3. India
    • 7.8.3.1. Key country dynamics
      • 7.8.3.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.8.3.1.1.1. Incidence Analysis
        • 7.8.3.1.1.2. Prevalence Analysis
        • 7.8.3.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.8.3.2. Competitive scenario
    • 7.8.3.3. Regulatory framework
    • 7.8.3.4. Reimbursement scenario
    • 7.8.3.5. India market estimates and forecasts, 2021 - 2033
  • 7.8.4. Australia
    • 7.8.4.1. Key country dynamics
      • 7.8.4.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.8.4.1.1.1. Incidence Analysis
        • 7.8.4.1.1.2. Prevalence Analysis
        • 7.8.4.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.8.4.2. Competitive scenario
    • 7.8.4.3. Regulatory framework
    • 7.8.4.4. Reimbursement scenario
    • 7.8.4.5. Australia market estimates and forecasts, 2021 - 2033
  • 7.8.5. South Korea
    • 7.8.5.1. Key country dynamics
      • 7.8.5.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.8.5.1.1.1. Incidence Analysis
        • 7.8.5.1.1.2. Prevalence Analysis
        • 7.8.5.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.8.5.2. Competitive scenario
    • 7.8.5.3. Regulatory framework
    • 7.8.5.4. Reimbursement scenario
    • 7.8.5.5. South Korea market estimates and forecasts, 2021 - 2033
  • 7.8.6. Thailand
    • 7.8.6.1. Key country dynamics
      • 7.8.6.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.8.6.1.1.1. Incidence Analysis
        • 7.8.6.1.1.2. Prevalence Analysis
        • 7.8.6.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.8.6.2. Competitive scenario
    • 7.8.6.3. Regulatory framework
    • 7.8.6.4. Reimbursement scenario
    • 7.8.6.5. Thailand market estimates and forecasts, 2021 - 2033
• 7.9. Latin America
  • 7.9.1. Brazil
    • 7.9.1.1. Key country dynamics
      • 7.9.1.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.9.1.1.1.1. Incidence Analysis
        • 7.9.1.1.1.2. Prevalence Analysis
        • 7.9.1.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.9.1.2. Competitive scenario
    • 7.9.1.3. Regulatory framework
    • 7.9.1.4. Reimbursement scenario
    • 7.9.1.5. Brazil market estimates and forecasts, 2021 - 2033
  • 7.9.2. Argentina
    • 7.9.2.1. Key country dynamics
      • 7.9.2.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.9.2.1.1.1. Incidence Analysis
        • 7.9.2.1.1.2. Prevalence Analysis
        • 7.9.2.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.9.2.2. Competitive scenario
    • 7.9.2.3. Regulatory framework
    • 7.9.2.4. Reimbursement scenario
    • 7.9.2.5. Argentina market estimates and forecasts, 2021 - 2033
• 7.10. MEA
  • 7.10.1. South Africa
    • 7.10.1.1. Key country dynamics
      • 7.10.1.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.10.1.1.1.1. Incidence Analysis
        • 7.10.1.1.1.2. Prevalence Analysis
        • 7.10.1.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.10.1.2. Competitive scenario
    • 7.10.1.3. Regulatory framework
    • 7.10.1.4. Reimbursement scenario
    • 7.10.1.5. South Africa market estimates and forecasts, 2021 - 2033
  • 7.10.2. Saudi Arabia
    • 7.10.2.1. Key country dynamics
      • 7.10.2.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.10.2.1.1.1. Incidence Analysis
        • 7.10.2.1.1.2. Prevalence Analysis
        • 7.10.2.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.10.2.2. Competitive scenario
    • 7.10.2.3. Regulatory framework
    • 7.10.2.4. Reimbursement scenario
    • 7.10.2.5. Saudi Arabia market estimates and forecasts, 2021 - 2033
  • 7.10.3. UAE
    • 7.10.3.1. Key country dynamics
      • 7.10.3.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.10.3.1.1.1. Incidence Analysis
        • 7.10.3.1.1.2. Prevalence Analysis
        • 7.10.3.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.10.3.2. Competitive scenario
    • 7.10.3.3. Regulatory framework
    • 7.10.3.4. Reimbursement scenario
    • 7.10.3.5. UAE market estimates and forecasts, 2021 - 2033
  • 7.10.4. Kuwait
    • 7.10.4.1. Key country dynamics
      • 7.10.4.1.1. Epidemiology & Patient Pool Estimate (2024/2025)
        • 7.10.4.1.1.1. Incidence Analysis
        • 7.10.4.1.1.2. Prevalence Analysis
        • 7.10.4.1.1.3. Diagnosed vs Undiagnosed Population Assessment
    • 7.10.4.2. Competitive scenario
    • 7.10.4.3. Regulatory framework
    • 7.10.4.4. Reimbursement scenario
    • 7.10.4.5. Kuwait market estimates and forecasts, 2021 - 2033

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
  • 8.2.1. Innovators
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2025
  • 8.3.4. Stryker
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Medtronic
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. MicroPort Scientific Corporation.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Johnson and Johnson
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Terumo Corporation
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Penumbra, Inc. (Boston Scientific Corporation)
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. BAL-T Group (Balt Extrusion SAS)
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. phenox GmbH ( Wallaby)
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Acandis GmbH
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. KANEKA CORPORATION
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives